In the second and final part of our funds of structured products roundup, we review how funds from Luxembourg, the Netherlands, Switzerland, Ireland and Canada performed in July 2025.
Forte Pharma Fund The Luxembourg domiciled Sicav fund aims to generate long-term returns consistent with the preservation of capital, through a strategy focused on structured notes linked to underlyings in the global pharmaceutical and biotechnology sectors. In July, the fund delivered a 3.7% gain, driven by strong performance from select Big Pharma holdings and the portfolio’s diversified geographic exposure. Strong fundamentals suggest the pharmaceutical sector is well-positioned to